Grifols (GIFLF) Minority Interest (2009 - 2025)
Grifols' (GIFLF) quarterly Minority Interest came in at $2.7 billion in Q4 2025, down 6.71% on a YoY basis from $2.9 billion in Q4 2024, and down 6.71% quarter-over-quarter from $2.9 billion in Q4 2024.
Analysis
Grifols (GIFLF) Minority Interest (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Minority Interest for 17 consecutive years, with $2.7 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Minority Interest fell 6.71% year-over-year to $2.7 billion; the trailing twelve-month figure through Dec 2025 stood at $2.7 billion (down 6.71% YoY), and the FY2025 full-year result was $2.6 billion, down 9.45% from the prior year.
- Minority Interest retreated to $2.7 billion in Q4 2025 per GIFLF's latest filing, from $2.9 billion in the prior quarter.
- Across five years, Minority Interest topped out at $2.9 billion in Q4 2024 and bottomed at $2.1 billion in Q4 2021.
- Historically, Minority Interest has averaged $2.5 billion across 5 years, with a median of $2.4 billion in 2022.
- The sharpest annual moves came in 2024 and 2025: Minority Interest gained 26.06% in 2024, then dropped 6.71% in 2025.
- Over 5 years, Minority Interest stood at $2.1 billion in 2021, then increased by 15.74% to $2.4 billion in 2022, then dropped by 2.8% to $2.3 billion in 2023, then gained by 26.06% to $2.9 billion in 2024, then fell by 6.71% to $2.7 billion in 2025.
- According to Business Quant data, Minority Interest over the past three periods registered $2.7 billion, $2.9 billion, and $2.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.71 Bn |
| Dec 31, 2024 | 2.91 Bn |
| Dec 31, 2023 | 2.31 Bn |
| Dec 31, 2022 | 2.37 Bn |
| Dec 31, 2021 | 2.05 Bn |
| Dec 31, 2020 | 1.92 Bn |
| Sep 30, 2020 | 2.06 Bn |
| Mar 31, 2020 | 1.84 Bn |
| Dec 31, 2019 | 2.24 Bn |
| Sep 30, 2019 | 578.62 Mn |
| Dec 31, 2018 | 537.65 Mn |
| Sep 30, 2018 | 2.73 Mn |
| Jun 30, 2018 | 4.59 Mn |
| Mar 31, 2018 | 584.68 Mn |
| Dec 31, 2017 | 5.75 Mn |
| Jun 30, 2017 | 6.36 Mn |
| Dec 31, 2016 | 7.01 Mn |
| Sep 30, 2016 | 4.51 Mn |
| Jun 30, 2016 | 4.69 Mn |
| Dec 31, 2015 | 5.69 Mn |